Matching articles for "multiple sclerosis"
Issue 1714 · October 28, 2024 Free
In Brief: Subcutaneous Ocrelizumab (Ocrevus Zunovo) for Multiple Sclerosis

Ocrevus Zunovo (Genentech), a subcutaneous (SC) formulation of the anti-CD20 monoclonal antibody ocrelizumab plus human recombinant hyaluronidase-ocsq has been approved by the FDA for treatment of primary…

Med Lett Drugs Ther. 2024 Oct 28; 66(1714):174 doi:10.58347/tml.2024.1714b
Ocrevus Zunovo (Genentech), a subcutaneous (SC) formulation of the anti-CD20 monoclonal antibody ocrelizumab plus human recombinant hyaluronidase-ocsq has been approved by the FDA for treatment of primary progressive and relapsing forms of multiple sclerosis (MS). Intravenous ocrelizumab (Ocrevus) , which was approved for the same indications in 2017, is one of the most commonly prescribed drugs for treatment of MS. Ocrelizumab remains the only drug approved for treatment of primary progressive MS.
Issue 1671 · March 6, 2023
Ublituximab (Briumvi) for Relapsing Multiple Sclerosis

The FDA has approved the recombinant chimeric anti-CD20 antibody ublituximab-xiiy ( Briumvi – TG Therapeutics) for IV treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically…

Med Lett Drugs Ther. 2023 Mar 6; 65(1671):36-8 doi:10.58347/tml.2023.1671c
The FDA has approved the recombinant chimeric anti-CD20 antibody ublituximab-xiiy ( Briumvi – TG Therapeutics) for IV treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Two other anti-CD20 antibodies, IV ocrelizumab (Ocrevus) and SC ofatumumab (Kesimpta) , are also FDA-approved for these indications.
Issue 1630 · August 9, 2021
Ponesimod (Ponvory) for Multiple Sclerosis

The FDA has approved ponesimod ( Ponvory – Janssen), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated…

Med Lett Drugs Ther. 2021 Aug 9; 63(1630):123-5
The FDA has approved ponesimod ( Ponvory – Janssen), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Ponesimod is the fourth oral S1P receptor modulator to be approved in the US for once-daily treatment of relapsing forms of MS; ozanimod (Zeposia) and siponimod (Mayzent) are also approved for use in adults, and fingolimod (Gilenya) is indicated for use in patients ≥10 years old.
Issue 1620 · March 22, 2021
Drugs for Multiple Sclerosis

Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations,…

Med Lett Drugs Ther. 2021 Mar 22; 63(1620):42-8
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations, and other drugs for managing symptoms such as fatigue, depression, and pain. Early use of disease-modifying therapy has improved clinical outcomes.
Issue 1614 · December 28, 2020
Ofatumumab (Kesimpta) for Multiple Sclerosis

The FDA has approved a subcutaneous formulation of the recombinant human anti-CD20 antibody ofatumumab ( Kesimpta – Novartis) for treatment of adults with relapsing forms of multiple sclerosis (MS),…

Med Lett Drugs Ther. 2020 Dec 28; 62(1614):203-5
The FDA has approved a subcutaneous formulation of the recombinant human anti-CD20 antibody ofatumumab ( Kesimpta – Novartis) for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Kesimpta is the second anti-CD20 antibody to be approved for these indications; IV ocrelizumab (Ocrevus) , which is also approved for treatment of primary progressive MS, was the first. An IV formulation of ofatumumab (Arzerra) has been available for treatment of chronic lymphocytic leukemia (CLL) since 2010.
Issue 1605 · August 24, 2020
Ozanimod (Zeposia) for Multiple Sclerosis

The FDA has approved ozanimod ( Zeposia – Celgene), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated…

Med Lett Drugs Ther. 2020 Aug 24; 62(1605):132-4
The FDA has approved ozanimod ( Zeposia – Celgene), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). It is the third oral S1P receptor modulator to be approved in the US for treatment of relapsing forms of MS; siponimod (Mayzent) is also indicated for use in adults, and fingolimod (Gilenya) is approved for use in patients ≥10 years old.
Issue 1585 · November 18, 2019
Cannabis and Cannabinoids

Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of…

Med Lett Drugs Ther. 2019 Nov 18; 61(1585):179-82
Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of cannabis. CBD, unlike THC, does not produce intoxication or euphoria.
Issue 1577 · July 29, 2019
Cladribine (Mavenclad) for Multiple Sclerosis

The FDA has approved cladribine ( Mavenclad – EMD Serono), a purine antimetabolite, for oral treatment of adults with relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and…

Med Lett Drugs Ther. 2019 Jul 29; 61(1577):118-20
The FDA has approved cladribine ( Mavenclad – EMD Serono), a purine antimetabolite, for oral treatment of adults with relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and active secondary progressive MS (SPMS), who cannot tolerate or have had an inadequate response to other drugs indicated for treatment of MS. It is not recommended for use in patients with clinically isolated syndrome (CIS). IV cladribine, which is FDA-approved for treatment of hairy cell leukemia, has been used off-label for treatment of MS.
Issue 1571 · May 6, 2019
Siponimod (Mayzent) - A New Drug for Multiple Sclerosis

The FDA has approved siponimod ( Mayzent – Novartis), a sphingosine 1-phosphate (S1P) receptor modulator, for oral treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically…

Med Lett Drugs Ther. 2019 May 6; 61(1571):70-2
The FDA has approved siponimod ( Mayzent – Novartis), a sphingosine 1-phosphate (S1P) receptor modulator, for oral treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Siponimod is the second S1P receptor modulator to be approved in the US; fingolimod (Gilenya) , which is approved for oral treatment of relapsing forms of MS in patients ≥10 years old, was the first. The purine antimetabolite cladribine (Mavenclad) was also recently approved for oral treatment of relapsing forms of MS and will be reviewed in a future issue.
Issue 1523 · June 19, 2017
Ocrelizumab (Ocrevus) for MS

The FDA has approved ocrelizumab ( Ocrevus – Genentech), a humanized anti-CD20 monoclonal antibody, for treatment of adults with primary progressive or relapsing multiple sclerosis (MS). It is the first…

Med Lett Drugs Ther. 2017 Jun 19; 59(1523):98-101
The FDA has approved ocrelizumab ( Ocrevus – Genentech), a humanized anti-CD20 monoclonal antibody, for treatment of adults with primary progressive or relapsing multiple sclerosis (MS). It is the first anti-CD20 monoclonal antibody to be approved for treatment of MS and the first disease-modifying drug to be approved in the US for primary progressive MS.
Issue 1503 · September 12, 2016
Daclizumab (Zinbryta) for Multiple Sclerosis

The FDA has approved daclizumab ( Zinbryta – Biogen/Abbvie), an interleukin-2 (IL-2) receptor blocking monoclonal antibody, for treatment of adults with relapsing forms of multiple sclerosis (MS). It is the…

Med Lett Drugs Ther. 2016 Sep 12; 58(1503):117-9
The FDA has approved daclizumab ( Zinbryta – Biogen/Abbvie), an interleukin-2 (IL-2) receptor blocking monoclonal antibody, for treatment of adults with relapsing forms of multiple sclerosis (MS). It is the first subcutaneously injected monoclonal antibody to be approved for treatment of MS.
Issue 1500 · August 1, 2016
Cannabis and Cannabinoids

In the US, 25 states and the District of Columbia now permit some medical use of botanical marijuana (Cannabis sativa) . It has been used for centuries to treat various ailments, but non-standardization of…

Med Lett Drugs Ther. 2016 Aug 1; 58(1500):97-8
In the US, 25 states and the District of Columbia now permit some medical use of botanical marijuana (Cannabis sativa) . It has been used for centuries to treat various ailments, but non-standardization of dosage makes available data difficult to interpret. Cannabis contains >60 pharmacologically active cannabinoids.
Issue 1496 · June 6, 2016
Drugs for Multiple Sclerosis

Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Treatment usually includes disease-modifying drugs, various other drugs for managing symptoms such as…

Med Lett Drugs Ther. 2016 Jun 6; 58(1496):71-4
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Treatment usually includes disease-modifying drugs, various other drugs for managing symptoms such as fatigue, depression, and pain, and corticosteroids for acute exacerbations.
Issue 1468 · May 11, 2015
Peginterferon Beta-1a (Plegridy) for Multiple Sclerosis

The FDA has approved a pegylated form of interferon beta-1a ( Plegridy – Biogen) for biweekly treatment of patients with relapsing multiple sclerosis (MS).

Med Lett Drugs Ther. 2015 May 11; 57(1468):67-9
The FDA has approved a pegylated form of interferon beta-1a ( Plegridy – Biogen) for biweekly treatment of patients with relapsing multiple sclerosis (MS).
Issue 1418 · June 10, 2013
Dimethyl Fumarate (Tecfidera) for Multiple Sclerosis

The FDA has approved dimethyl fumarate ( Tecfidera – Biogen Idec), formerly called BG-12, for treatment of relapsing forms of multiple sclerosis (MS). It is the third oral drug to be approved in recent years…

Med Lett Drugs Ther. 2013 Jun 10; 55(1418):45-7
The FDA has approved dimethyl fumarate ( Tecfidera – Biogen Idec), formerly called BG-12, for treatment of relapsing forms of multiple sclerosis (MS). It is the third oral drug to be approved in recent years for this indication.
Issue 1403 · November 12, 2012
New Drugs for Multiple Sclerosis

In recent years, several new drugs have been approved by the FDA for use in multiple sclerosis (MS), and many others are in the pipeline. Most recently, teriflunomide ( Aubagio – Genzyme) became the second…

Med Lett Drugs Ther. 2012 Nov 12; 54(1403):89-91
In recent years, several new drugs have been approved by the FDA for use in multiple sclerosis (MS), and many others are in the pipeline. Most recently, teriflunomide ( Aubagio – Genzyme) became the second oral drug to be approved by the FDA for treatment of relapsing forms of MS.
Issue 1366 · June 13, 2011
Dextromethorphan/Quinidine (Nuedexta) for Pseudobulbar Affect

The FDA has approved Nuedexta (Avanir) , a fixed-dose combination of the cough suppressant dextromethorphan hydrobromide and the antiarrhythmic quinidine sulfate, for oral treatment of pseudobulbar affect. The…

Med Lett Drugs Ther. 2011 Jun 13; 53(1366):46-7
The FDA has approved Nuedexta (Avanir) , a fixed-dose combination of the cough suppressant dextromethorphan hydrobromide and the antiarrhythmic quinidine sulfate, for oral treatment of pseudobulbar affect. The combination is the first treatment approved by the FDA for this indication. Studies to support the effectiveness of Nuedexta were performed in patients with underlying amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS); the drug has not been shown to be safe or effective in other types of emotional lability.
Issue 1353 · December 13, 2010
Oral Fingolimod (Gilenya) for Multiple Sclerosis

The FDA has approved the marketing of fingolimod ( Gilenya – Novartis) to reduce the frequency of clinical exacerbations and delay the accumulation of physical disability in patients with relapsing forms of…

Med Lett Drugs Ther. 2010 Dec 13; 52(1353):98-100
The FDA has approved the marketing of fingolimod ( Gilenya – Novartis) to reduce the frequency of clinical exacerbations and delay the accumulation of physical disability in patients with relapsing forms of multiple sclerosis (MS). Fingolimod is the first oral drug approved for this indication.
Issue 1350 · November 1, 2010
Interferon Beta-1b (Extavia) for Multiple Sclerosis

The FDA has approved a new interferon beta-1b product ( Extavia – Novartis) for treatment of relapsing forms of multiple sclerosis (MS). Extavia is identical to Betaseron (Bayer); both are produced in the…

Med Lett Drugs Ther. 2010 Nov 1; 52(1350):86-7
The FDA has approved a new interferon beta-1b product ( Extavia – Novartis) for treatment of relapsing forms of multiple sclerosis (MS). Extavia is identical to Betaseron (Bayer); both are produced in the same factory and packaged separately.
Issue 1347 · September 20, 2010
Dalfampridine (Ampyra) for MS

The FDA has approved the use of dalfampridine (4-aminopyridine; Ampyra – Acorda), a potassium channel blocker, to improve walking speed in patients with multiple sclerosis (MS). Walking speed is considered a…

Med Lett Drugs Ther. 2010 Sep 20; 52(1347):73-4
The FDA has approved the use of dalfampridine (4-aminopyridine; Ampyra – Acorda), a potassium channel blocker, to improve walking speed in patients with multiple sclerosis (MS). Walking speed is considered a reliable clinical measure of impairment in patients with MS.
Issue 1330 · January 25, 2010
Medical Marijuana

Fourteen states in the US - Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont and Washington - now permit, or soon will permit, some…

Med Lett Drugs Ther. 2010 Jan 25; 52(1330):5-6
Fourteen states in the US - Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont and Washington - now permit, or soon will permit, some medical use of marijuana (Cannabis sativa) . In some states, licensed facilities dispense botanical cannabis by prescription. In others, limited self-cultivation is permitted for medical use.
Issue 1307 · March 9, 2009
Alemtuzumab (Campath) Off-Label for Relapsing Multiple Sclerosis

Alemtuzumab (Campath) , a genetically engineered, humanized monoclonal antibody currently approved to treat B-cell chronic lymphocytic leukemia (BCLL) and used off-label for induction therapy in solid organ…

Med Lett Drugs Ther. 2009 Mar 9; 51(1307):17-8
Alemtuzumab (Campath) , a genetically engineered, humanized monoclonal antibody currently approved to treat B-cell chronic lymphocytic leukemia (BCLL) and used off-label for induction therapy in solid organ transplants, is now also being tried off-label for treatment of relapsing multiple sclerosis (MS).
Issue 1249 · December 4, 2006
Intravenous Immunoglobulin (IVIG)

Intravenous immunoglobulin (IVIG) has 6 FDA approved indications and is prescribed off-label for many others. How many of these uses are justified is controversial.

Med Lett Drugs Ther. 2006 Dec 4; 48(1249):101-2
Intravenous immunoglobulin (IVIG) has 6 FDA approved indications and is prescribed off-label for many others. How many of these uses are justified is controversial.
Issue 1243 · September 11, 2006 Free
In Brief: Natalizumab (Tysabri) Returns

Soon after The Medical Letter first reviewed use of natalizumab ( Tysabri – Biogen Idec and Elan) for treatment of relapsing forms of multiple sclerosis (MS) (Med Lett Drugs Ther 2005; 47:13) , the drug was…

Med Lett Drugs Ther. 2006 Sep 11; 48(1243):76
Soon after The Medical Letter first reviewed use of natalizumab ( Tysabri – Biogen Idec and Elan) for treatment of relapsing forms of multiple sclerosis (MS) (Med Lett Drugs Ther 2005; 47:13) , the drug was withdrawn from the market. The unpublished clinical trials that led to its approval by the FDA have since been published, and now the drug has been returned to the market with prescribing restrictions. Natalizumab decreases the number of relapses and new brain lesions in patients with MS. It was withdrawn because progressive multifocal leukoencephalopathy (PML) occurred in 3 (of about 3000) patients being treated with the drug; two were taking the drug in combination with interferon beta for MS, and one was taking it with azathioprine for Crohn’s disease. PML is an opportunistic infection of the brain, caused by reactivation of the JC virus in immunosuppressed patients, that often causes death or severe neurological disability. There is no treatment for PML. The publication of the natalizumab clinical trials in MS provided information on the drug’s effect on the progression of disability, which was not available when it was first reviewed here. In one study, combination therapy with natalizumab and interferon beta-1a for 2 years led to an estimated cumulative probability of progression of 23%, compared to 29% with interferon beta-1a alone (RA Rudick et al. N Engl J Med 2006; 354:911) . In the second study, the estimated cumulative probability of progression over 2 years was 17% with natalizumab alone and 29% with placebo (CH Polman et al. N Engl J Med 2006; 354:899) . Download U.S. English
Issue 1204 · March 14, 2005 Free
In Brief: Natalizumab (Tysabri) Withdrawn

The February 14th issue of The Medical Letter reviewed natalizumab ( Tysabri - Biogen Idec), a new monoclonal antibody that was granted accelerated approval because it decreased the number of relapses in…

Med Lett Drugs Ther. 2005 Mar 14; 47(1204):21
The February 14th issue of The Medical Letter reviewed natalizumab ( Tysabri - Biogen Idec), a new monoclonal antibody that was granted accelerated approval because it decreased the number of relapses in patients with multiple sclerosis. On February 28th, the FDA issued a Public Health Advisory announcing that marketing of the drug had been suspended because 2 patients who had been treated with natalizumab for more than 2 years had developed progressive multifocal leukoencephalopathy, a rare, often fatal disease (www.fda.gov) .
Issue 1202 · February 14, 2005
Natalizumab (Tysabri) for Relapsing Multiple Sclerosis

Natalizumab, a recombinant humanized monoclonal antibody, has received accelerated approval from the FDA for intravenous treatment of relapsing forms of multiple sclerosis (MS). The beta interferons and…

Med Lett Drugs Ther. 2005 Feb 14; 47(1202):13-5
Natalizumab, a recombinant humanized monoclonal antibody, has received accelerated approval from the FDA for intravenous treatment of relapsing forms of multiple sclerosis (MS). The beta interferons and glatiramer acetate are widely used for treatment of MS; they generally reduce the number of relapses by about 30% compared to placebo, and have been shown to be safe and effective for periods ranging from 4 to 10 years.
Issue 1196 · November 22, 2004
L-Carnitine

Carnitine is a naturally occurring amino acid derivative essential for transport of long-chain fatty acids into mitochondria. It is advertised on the Internet as a dietary supplement that can promote weight…

Med Lett Drugs Ther. 2004 Nov 22; 46(1196):95-6
Carnitine is a naturally occurring amino acid derivative essential for transport of long-chain fatty acids into mitochondria. It is advertised on the Internet as a dietary supplement that can promote weight loss, increase energy, enhance athletic performance and slow aging. Levocarnitine ( Carnitor - Sigma-Tau) has been FDA approved for oral and parenteral treatment of primary carnitine deficiency since 1986. Products containing levocarnitine and its synthetic derivative acetyl-L-carnitine are available as dietary supplements in the US.
Issue 1141 · October 14, 2002
Beta Interferons for Multiple Sclerosis

Three beta interferons are widely used in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).

Med Lett Drugs Ther. 2002 Oct 14; 44(1141):88-9
Three beta interferons are widely used in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).
Issue 979 · July 19, 1996
Interferon Beta-1a for Relapsing Multiple Sclerosis

Interferon β-1a ( Avonex - Biogen), a recombinant form of human interferon β, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing forms of multiple sclerosis (MS).…

Med Lett Drugs Ther. 1996 Jul 19; 38(979):63-4
Interferon β-1a ( Avonex - Biogen), a recombinant form of human interferon β, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing forms of multiple sclerosis (MS). Interferon β-1a ( Betaseron - Berlex), a recombinant analog of interferon β that differs from interferon β-1a in having a serine substituted for a cysteine and in not being glycosylated, was previously approved for this indication (Medical Letter, 35:61, 1993; BW van Oosten et al, Drugs, 49:200, 1995).
Issue 917 · March 4, 1994
Intrathecal Baclofen for Spasticity

An intrathecal formulation of the muscle relaxant baclofen ( Lioresal Intrathecal - Medtronic) has been approved by the US Food and Drug Administration for treatment of spasticity due to multiple sclerosis…

Med Lett Drugs Ther. 1994 Mar 4; 36(917):21-2
An intrathecal formulation of the muscle relaxant baclofen ( Lioresal Intrathecal - Medtronic) has been approved by the US Food and Drug Administration for treatment of spasticity due to multiple sclerosis (MS) or spinal cord injury. Its use requires subcutaneous implantation of a drug pump, which infuses the drug into the subarachnoid space. Baclofen ( Lioresal [Ciba-Geigy], and others) has been available as an oral formulation for many years (Medical Letter 20:43, 1978), but its use has been limited by central-nervous-system effects such as drowsiness and confusion.
Issue 900 · July 9, 1993
Interferon Beta-1b for Multiple Sclerosis

Interferon β-1b ( Betaseron - Berlex), an analog of human interferon β pro-duced in E. coli, may soon be approved by the US Food and Drug Administration for treatment of relapsing-remitting multiple…

Med Lett Drugs Ther. 1993 Jul 9; 35(900):61-2
Interferon β-1b ( Betaseron - Berlex), an analog of human interferon β pro-duced in E. coli, may soon be approved by the US Food and Drug Administration for treatment of relapsing-remitting multiple sclerosis (MS), the most common form of the disease (G Mitchell, Med Clin North Am, 77:231, 1993).